Internal medicine

Dermatology

Receptor

Enzyme

Chemistry

Adverse effect

Psoriatic arthritis

Cyclic adenosine monophosphate

Phosphodiesterase inhibitor

COPD

Adenosine

Atopic dermatitis

Roflumilast

Adenosine monophosphate

Psoriasis

Apremilast

Biochemistry

Phosphodiesterase

Medicine

Pharmacology

Psoriasis Targets and Therapy

Abstract: Psoriasis is a chronic immune-mediated inflammatory disorder. Phosphodiesterase-4 (PDE-4) is an enzyme that mediates inflammatory responses and plays a role in psoriasis pathogenesis. PDE-4 degrades its substrate cyclic adenosine monophosphate (cAMP) to adenosine monophosphate (AMP), which subsequently leads to the production of pro-inflammatory mediators. Inhibitors of PDE-4 work by blocking the degradation of cAMP, which leads to a reduction in inflammation. Apremilast is the only approved oral PDE-4 inhibitor for the treatment of psoriasis. While it is effective for some patients, it may be limited by adverse effects in others. A topical PDE-4 inhibitor, roflumilast, is being investigated in psoriasis and showing promising results. Crisaborole, a topical PDE-4 inhibitor approved for use in atopic dermatitis, has also been investigated in psoriasis. This is an updated comprehensive review to summarize the currently available evidence for the PDE-4 inhibitors apremilast, roflumilast and crisaborole in the treatment of psoriasis, with a focus on data from randomized clinical trials. Keywords: psoriasis, PDE-4, phosphodiesterase inhibitors, topical therapies

Phosphodiesterase-4 Inhibition in Psoriasis